neuroblastoma
Lynparza, Ceralasertib Combo Trial Provides Clues on Biomarkers of Response in Pediatric Cancer
Premium
In the tumor-agnostic study, pediatric patients with 11q loss and other alterations associated with replication stress benefited from the dual PARP-ATR inhibitor treatment.
Massey Cancer Center Researchers Exploring SHP2 Inhibitor Potential in Pediatric Neuroblastoma
Premium
Based on data from tumor models, researchers are working with the NCI to explore the potential of SHP2 inhibitors with maintenance therapy in high-risk neuroblastoma with NF1 loss.
A multiomic study out of TGen and the Beat Childhood Cancer Research Consortium found potentially actionable tumor changes at the point of disease relapse.
Kuur Therapeutics Reports Initial Activity of CAR NK-Cell Therapy in Neuroblastoma
In a Phase I study, out of 10 evaluable patients, one had a complete response, one had a partial response, and three experienced stable disease.
CAR T-Cell Therapy Shows Signs of Anti-Tumor Activity in Pediatric Neuroblastoma Patients
The GD2-directed treatment had varying degrees of activity in a small Phase I study, though further improvements are needed to achieve durable responses.